Cargando…

Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension

BACKGROUND & AIMS: Liver resection (LR) in patients with hepatocellular carcinoma (HCC) and clinically significant portal hypertension (CSPH) defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg is not encouraged. Here, we reappraised the outcomes of patients with cirrhosis and CSPH who...

Descripción completa

Detalles Bibliográficos
Autores principales: Azoulay, Daniel, Ramos, Emilio, Casellas-Robert, Margarida, Salloum, Chady, Lladó, Laura, Nadler, Roy, Busquets, Juli, Caula-Freixa, Celia, Mils, Kristel, Lopez-Ben, Santiago, Figueras, Joan, Lim, Chetana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689549/
https://www.ncbi.nlm.nih.gov/pubmed/33294830
http://dx.doi.org/10.1016/j.jhepr.2020.100190
_version_ 1783613884817473536
author Azoulay, Daniel
Ramos, Emilio
Casellas-Robert, Margarida
Salloum, Chady
Lladó, Laura
Nadler, Roy
Busquets, Juli
Caula-Freixa, Celia
Mils, Kristel
Lopez-Ben, Santiago
Figueras, Joan
Lim, Chetana
author_facet Azoulay, Daniel
Ramos, Emilio
Casellas-Robert, Margarida
Salloum, Chady
Lladó, Laura
Nadler, Roy
Busquets, Juli
Caula-Freixa, Celia
Mils, Kristel
Lopez-Ben, Santiago
Figueras, Joan
Lim, Chetana
author_sort Azoulay, Daniel
collection PubMed
description BACKGROUND & AIMS: Liver resection (LR) in patients with hepatocellular carcinoma (HCC) and clinically significant portal hypertension (CSPH) defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg is not encouraged. Here, we reappraised the outcomes of patients with cirrhosis and CSPH who underwent LR for HCC in highly specialised liver centres. METHODS: This was a retrospective multicentre study from 1999 to 2019. Predictors for postoperative liver decompensation and textbook outcomes were identified. RESULTS: In total, 79 patients with a median age of 65 years were included. The Child-Pugh grade was A in 99% of patients, and the median model for end-stage liver disease (MELD) score was 8. The median HVPG was 12 mmHg. Major hepatectomies and laparoscopies were performed in 28% and 34% of patients, respectively. Ninety-day mortality and severe morbidity rates were 6% and 27%, respectively. Postoperative and persistent liver decompensation occurred in 35% and 10% of patients at 3 months. Predictors of liver decompensation included increased preoperative HVPG (p = 0.004), increased serum total bilirubin (p = 0.02), and open approach (p = 0.03). Of the patients, 34% achieved a textbook outcome, of which the laparoscopic approach was the sole predictor (p = 0.004). The 5-year overall survival and recurrence-free survival rates were 55% and 43%, respectively. CONCLUSIONS: Patients with cirrhosis, HCC and HVPG ≥10 mmHg can undergo LR with acceptable mortality, morbidity, and liver decompensation rates. The laparoscopic approach was the sole predictor of a textbook outcome. LAY SUMMARY: Patients with cirrhosis, hepatocellular carcinoma, and clinically significant portal hypertension (defined as a hepatic venous pressure gradient ≥10 mmHg) can undergo resection with acceptable mortality, morbidity, liver decompensation rates, and a textbook outcome. These results can be achieved in selected patients with preserved liver function, good general status, and sufficient remnant liver volume.
format Online
Article
Text
id pubmed-7689549
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76895492020-12-07 Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension Azoulay, Daniel Ramos, Emilio Casellas-Robert, Margarida Salloum, Chady Lladó, Laura Nadler, Roy Busquets, Juli Caula-Freixa, Celia Mils, Kristel Lopez-Ben, Santiago Figueras, Joan Lim, Chetana JHEP Rep Research Article BACKGROUND & AIMS: Liver resection (LR) in patients with hepatocellular carcinoma (HCC) and clinically significant portal hypertension (CSPH) defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg is not encouraged. Here, we reappraised the outcomes of patients with cirrhosis and CSPH who underwent LR for HCC in highly specialised liver centres. METHODS: This was a retrospective multicentre study from 1999 to 2019. Predictors for postoperative liver decompensation and textbook outcomes were identified. RESULTS: In total, 79 patients with a median age of 65 years were included. The Child-Pugh grade was A in 99% of patients, and the median model for end-stage liver disease (MELD) score was 8. The median HVPG was 12 mmHg. Major hepatectomies and laparoscopies were performed in 28% and 34% of patients, respectively. Ninety-day mortality and severe morbidity rates were 6% and 27%, respectively. Postoperative and persistent liver decompensation occurred in 35% and 10% of patients at 3 months. Predictors of liver decompensation included increased preoperative HVPG (p = 0.004), increased serum total bilirubin (p = 0.02), and open approach (p = 0.03). Of the patients, 34% achieved a textbook outcome, of which the laparoscopic approach was the sole predictor (p = 0.004). The 5-year overall survival and recurrence-free survival rates were 55% and 43%, respectively. CONCLUSIONS: Patients with cirrhosis, HCC and HVPG ≥10 mmHg can undergo LR with acceptable mortality, morbidity, and liver decompensation rates. The laparoscopic approach was the sole predictor of a textbook outcome. LAY SUMMARY: Patients with cirrhosis, hepatocellular carcinoma, and clinically significant portal hypertension (defined as a hepatic venous pressure gradient ≥10 mmHg) can undergo resection with acceptable mortality, morbidity, liver decompensation rates, and a textbook outcome. These results can be achieved in selected patients with preserved liver function, good general status, and sufficient remnant liver volume. Elsevier 2020-10-08 /pmc/articles/PMC7689549/ /pubmed/33294830 http://dx.doi.org/10.1016/j.jhepr.2020.100190 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Azoulay, Daniel
Ramos, Emilio
Casellas-Robert, Margarida
Salloum, Chady
Lladó, Laura
Nadler, Roy
Busquets, Juli
Caula-Freixa, Celia
Mils, Kristel
Lopez-Ben, Santiago
Figueras, Joan
Lim, Chetana
Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
title Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
title_full Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
title_fullStr Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
title_full_unstemmed Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
title_short Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
title_sort liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689549/
https://www.ncbi.nlm.nih.gov/pubmed/33294830
http://dx.doi.org/10.1016/j.jhepr.2020.100190
work_keys_str_mv AT azoulaydaniel liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT ramosemilio liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT casellasrobertmargarida liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT salloumchady liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT lladolaura liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT nadlerroy liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT busquetsjuli liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT caulafreixacelia liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT milskristel liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT lopezbensantiago liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT figuerasjoan liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension
AT limchetana liverresectionforhepatocellularcarcinomainpatientswithclinicallysignificantportalhypertension